Securities Code: 301290
Securities Abbreviation: Dongxing Medical
Announcement Number: 2026-036
Jiangsu Dongxing Smart Medical Technology Co., Ltd.
Announcement on the Progress of Major Asset Restructuring
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
I. Transaction Overview
Jiangsu Dongxing Smart Medical Technology Co., Ltd. (hereinafter referred to as the "Company" or "Listed Company") intends to acquire 90% equity of Wuhan Yijiaobao Biological Materials Co., Ltd. (hereinafter referred to as "Wuhan Yijiaobao" or "Target Company") held by Bao Shijun and his controlled entity Hubei Tianhui Technology Development Co., Ltd. (hereinafter referred to as the "Transaction Counterparty") through cash payment (hereinafter referred to as the "Transaction"). Upon completion of the Transaction, the Listed Company will hold 90% equity of Wuhan Yijiaobao, and Wuhan Yijiaobao will become a subsidiary controlled by the Listed Company.
Based on preliminary research and calculations, the Transaction is expected to constitute a major asset restructuring as stipulated by the "Measures for the Administration of Major Asset Restructuring of Listed Companies." The Transaction does not involve the issuance of shares by the Listed Company, does not constitute a related-party transaction, and will not result in a change of the Listed Company's controlling shareholder and actual controller.
II. Transaction Progress